From: Megaprostheses for the revision of infected hip arthroplasties with severe bone loss
Outcome | Compared groups | Survival at 2Â years (CI95%) | Survival at 5Â years (CI95%) | p-value |
---|---|---|---|---|
Infection free survival | Coated | 91.7% (53.9–98.8) | 80.2% (40.2–94.8) | 0.17 |
Uncoated | 100% (100–100) | 100% (100–100) | ||
Uncoated | 100% (100–100) | 100% (100–100) | 0.22 | |
PorAg® | 100% (100–100) | 100% (100–100) | ||
DAC® | 100% (100–100) | 66.7% (5.4–94.5) | ||
PorAg® + DAC® | 75% (12.8–96.1) | 75% (12.8–96.1) | ||
Cemented | 100% (100–100) | 100% (100–100) | 0.50 | |
Cementless | 94.1% (65–99.2) | 87.4% (58.1–96.7) | ||
Major revision free survival | Coated | 91.7% (53.9–98.8) | 91.7% (53.9–98.8) | 0.97 |
Uncoated | 100% (100–100) | 88.9% (43.3–98.4) | ||
Uncoated | 100% (100–100) | 88.9% (43.3–98.4) | 0.29 | |
PorAg® | 100% (100–100) | 100% (100–100) | ||
DAC® | 66.7% (5.4–94.5) | 66.7% (5.4–94.5) | ||
PorAg® + DAC® | 100% (100–100) | 100% (100–100) | ||
Cemented | 75% (12.8–96.1) | 75% (12.8–96.1) | 0.19 | |
Cementless | 100% (100–100) | 92.3% (56.6–98.9) | ||
Overall revision free survival | 83.35 (50.7–93.94) | 83.35 (50.7–93.94) |  |